



## **Synta Pharmaceuticals to Present at Bear Stearns Conference and International Melanoma Congress**

September 6, 2006

Bear Stearns Presentation Will Include Top-line Results of STA-4783 Phase 2 Trial in Metastatic Melanoma

Full Study Results Will Be Presented at International Joint Melanoma Congress Later in the Week

Lexington, MA -September 6, 2006- Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing and commercializing small-molecule drugs to treat severe medical conditions, today announced that the company will be presenting at the Bear Stearns 19th Annual HealthCare Conference on September 11, 2006 and at the joint meeting of the Congress on Perspectives in Melanoma X and the Third International Melanoma Research Congress on September 16, 2006.

At the Bear Stearns conference, Safi Bahcall, Ph.D., president and chief executive officer of Synta, will provide an overview of the company's programs and discuss top-line results from a Phase 2b trial of Synta's novel investigational oncology agent STA-4783 in metastatic melanoma. The presentation will take place at 10:00 a.m. EDT at the Grand Hyatt Hotel in New York City. A breakout session will follow.

At the Congress on Perspectives in Melanoma X, Steven O'Day, M.D., principal investigator of the Phase 2b trial of STA-4783 in metastatic melanoma, will discuss the full study results. The presentation will take place at the Hotel van Oranje in Noordwijk ann Zee, just outside Amsterdam in The Netherlands. This Congress brings together international melanoma researchers and clinicians from both the Perspectives in Melanoma committee and the Society for Melanoma Research. For more information on the Congress, visit [www.imedex.com/announcements/251.asp](http://www.imedex.com/announcements/251.asp).

### About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule drugs to extend and enhance the lives of patients with severe medical conditions, including chronic inflammatory disease and cancer. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of internally developed drug candidates in clinical and pre-clinical development targeting large therapeutic markets. For more information, please see [www.syntapharma.com](http://www.syntapharma.com).